These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 7151620)
41. Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC). Holm NT; Abreo F; Johnson LW; Li BD; Chu QD Breast Cancer Res Treat; 2009 Jan; 113(2):293-9. PubMed ID: 18270814 [TBL] [Abstract][Full Text] [Related]
42. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. Millar EK; Graham PH; O'Toole SA; McNeil CM; Browne L; Morey AL; Eggleton S; Beretov J; Theocharous C; Capp A; Nasser E; Kearsley JH; Delaney G; Papadatos G; Fox C; Sutherland RL J Clin Oncol; 2009 Oct; 27(28):4701-8. PubMed ID: 19720911 [TBL] [Abstract][Full Text] [Related]
43. [Assay of DNA content and estrogen receptor status in human breast cancer]. Chen GJ; Shao YF; Shan Y Zhonghua Zhong Liu Za Zhi; 1994 Nov; 16(6):461-4. PubMed ID: 7720507 [TBL] [Abstract][Full Text] [Related]
44. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer. Schrama JG; Baars JW; Holtkamp MJ; Schornagel JH; Beijnen JH; Rodenhuis S Bone Marrow Transplant; 2001 Jul; 28(2):173-80. PubMed ID: 11509935 [TBL] [Abstract][Full Text] [Related]
45. Castration for primary inoperable or recurrent breast carcinoma. Fracchia AA; Farrow JH; DePalo AJ; Connolly DP; Huvos AG Surg Gynecol Obstet; 1969 Jun; 128(6):1226-34. PubMed ID: 5781848 [No Abstract] [Full Text] [Related]
47. [Operable carcinoma of the breast. Prognostic value of estradiol receptors. Preliminary report (author's transl)]. Cheix F; Biron A; Bailly C; Mayer M; Pommatau E; Saez S Nouv Presse Med; 1980 Mar; 9(13):933-5. PubMed ID: 7360626 [TBL] [Abstract][Full Text] [Related]
48. [Experimental and clinical aspects of hormone therapy in breast cancer (author's transl)]. Maass H; Jonat W Arch Geschwulstforsch; 1981; 51(7):623-9. PubMed ID: 7337544 [TBL] [Abstract][Full Text] [Related]
49. Transsphenoidal hypophysectomy in disseminated breast cancer. Schwarz M; Tindall GT; Nixon DW South Med J; 1981 Mar; 74(3):315-7. PubMed ID: 6164101 [TBL] [Abstract][Full Text] [Related]
50. [Breast cancer in the early clinical stages. Results of treatment]. Molina Esquivel J; Vargas Sandoval G; García Siller I; Velázquez López J; Soto de León M Ginecol Obstet Mex; 1982 Oct; 50(306):279-81. PubMed ID: 7186867 [No Abstract] [Full Text] [Related]
51. Clinical correlations of steroid receptors and male breast cancer. Everson RB; Lippman ME; Thompson EB; McGuire WL; Wittliff JL; De Sombre ER; Jensen EV; Singhakowinta A; Brooks SC; Neifeld JP Cancer Res; 1980 Apr; 40(4):991-7. PubMed ID: 7357565 [TBL] [Abstract][Full Text] [Related]
52. Relationship of cytoplasmic and nuclear estrogen receptors and progesterone receptors in human breast cancer. Romić-Stojković R; Gamulin S Cancer Res; 1980 Dec; 40(12):4821-5. PubMed ID: 7438115 [TBL] [Abstract][Full Text] [Related]
53. Observations on short-term and long-term surveys of breast cancer by the American College of Surgeons. I. Significance of the number of axillary nodes and II. Estrogen receptor assay in the U.S. in 1977. Nemoto T; Vana J; Natarajan N; Bedwani R; Mettlin C Int Adv Surg Oncol; 1981; 4():209-39. PubMed ID: 7251174 [No Abstract] [Full Text] [Related]
54. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639 [TBL] [Abstract][Full Text] [Related]
55. Autotransplants in men with breast cancer. ABMTR Breast Cancer Working Committee. Autologous Blood and Marrow Transplant Registry. McCarthy P; Hurd D; Rowlings P; Crump M; Gale R; Lazarus H; Vaughan W; Weinberger B; Wiemann M; Freytes C; Cirenza E; Antman K Bone Marrow Transplant; 1999 Aug; 24(4):365-8. PubMed ID: 10467324 [TBL] [Abstract][Full Text] [Related]
56. Changes in survival during the past two decades for breast cancer at the Kyoto University Hospital. Ueno M; Kiba T; Nishimura T; Kitano T; Yanagihara K; Yoshikawa K; Ishiguro H; Teramukai S; Fukushima M; Kato H; Inamoto T Eur J Surg Oncol; 2007 Aug; 33(6):696-9. PubMed ID: 17376645 [TBL] [Abstract][Full Text] [Related]
57. Receptor for advanced glycation end products (RAGE)--soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Tesarová P; Kalousová M; Jáchymová M; Mestek O; Petruzelka L; Zima T Cancer Invest; 2007 Dec; 25(8):720-5. PubMed ID: 18058469 [TBL] [Abstract][Full Text] [Related]
58. Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy. Huber KE; Carey LA; Wazer DE Semin Radiat Oncol; 2009 Oct; 19(4):204-10. PubMed ID: 19732684 [TBL] [Abstract][Full Text] [Related]
59. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642). Costanza ME; Berry D; Henderson IC; Ratain MJ; Wu K; Shapiro C; Duggan D; Kalra J; Berkowitz I; Lyss AP Clin Cancer Res; 1995 Jul; 1(7):699-704. PubMed ID: 9816035 [TBL] [Abstract][Full Text] [Related]
60. [Therapy of generalized bone metastases of breast cancer by hypophysectomy]. Krejcí D; Hladík M Cesk Neurol; 1969 Jul; 32(4):200-2. PubMed ID: 5795009 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]